Information Provided By:
Fly News Breaks for July 1, 2016
GALT
Jul 1, 2016 | 08:46 EDT
Roth Capital analyst Sa'ar Yaniv resumed coverage of Galectin Therapeutics with a Buy rating and $3 price target.
News For GALT From the Last 2 Days
There are no results for your query GALT